The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
5
Cancer Therapy and Research Center, Institution for Drug Development
San Antonio, Texas, United States
To characterize the pharmacokinetic profile of patupilone including any potential metabolite(s) in blood/plasma as well as the total radioactivity in blood and plasma.
Time frame: one week
Safety and tolerability will be assessed by AEs, SAEs and out of range lab values.
Time frame: every 6 weeks
Radiological scans will also be completed at approximately 6 weeks to asses anti-tumor activity.
Time frame: every 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.